FSD Pharma Inc. (HUGE) News
Filter HUGE News Items
HUGE News Results
|Loading, please wait...|
HUGE News Highlights
- 500 - Internal server error
- 500 - Internal server error
Latest HUGE News From Around the Web
Below are the latest news stories about FSD Pharma Inc that investors may wish to consider to help them evaluate HUGE as an investment opportunity.
InvestmentPitch Media Video Discusses FSD Pharma's Termination of its CEO, Dr. Raza Bokhari, for Cause - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - July 28, 2021) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a specialty, biotech pharmaceutical R&D company, has terminated its CEO, Dr. Raza Bokhari, for cause. Following the company's shareholder meeting on May 14, 2021, Dr. Raza Bokhari was placed on administrative leave while a special committee comprised of two independent directors investigated various concerns regarding Dr. Bokhari's actions in his capacity as CEO.InvestmentPitch
TORONTO, July 27, 2021--FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) (the "Company" or "FSD") announced today that the board of directors had terminated the employment of the Company’s Chief Executive Officer, Dr. Raza Bokhari for cause.
FSD Pharma Inc. is pleased to announce the appointment of Mr. Adnan Bashir as an independent member of its Board of Directors, upon the recommendation of the Companys Compensation, Nomination and Governance Committee.
Fsd Pharma Inc Cl B (NASDAQ: HUGE) shares fell -4.00% to end trading Wednesday at $1.68 per share - a net change of $-0.07. Shares traded between $1.74 and $1.65 throughout the day. 390416 shares of Fsd Pharma Inc Cl B exchanged hands. Visit Fsd Pharma Inc Cl Bs profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Fsd Pharma Inc Cl B and to follow the companys latest updates, you can visit the companys profile page here: Fsd Pharma Inc Cl Bs Profile . For more news on the financial markets be su...
FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9) announced that the slate of board of directors nominees brought forward by a group of concerned shareholders received the necessary votes at the companys annual general and special meeting on May 14. The nominees of the concerned group, led by Anthony Durkacz and Zeeshan Saeed, were each elected, along with Frank Lavelle and Donal Carroll, to hold office for the ensuing year. However, following his election, Lavelle resigned, the company said. Nitin Kaushal and Larry Latowsky are the boards remaining two directors. We are pleased to see that FSD shareholders have shown their overwhelming support for the concerned shareholders and the concerned shareholders nominees, Durkacz and Saeed said in a statement. We look forward to restoring FSD ...
FSD Pharma Inc. Announces Results of the Annual General and Special Meeting of Shareholders Nominees of the Concerned Shareholders Elected to the Board of Directors
FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) (the Company or FSD ) is pleased to announce the results of its annual general and special meeting of the shareholders held on May 14 th , 2021 (the Meeting ) at which 54.17% of the votes attached to the issued and outstanding Class B Subordinate Voting Shares ( Class B Shares ) and Class A Multiple Voting Shares ( Class A Shares ) were represented.
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the "Company" or "FSD Pharma") announced today that it has filed a criminal complaint with Toronto Police Services, Financial Crimes Unit, against Mr. Donal Carroll, the Company''s former chief financial officer.
TORONTO, May 12, 2021 /PRNewswire/ - On Monday, May 10, 2021, at the request of Messrs. Anthony Durkacz and Zeeshan Saeed, founding shareholders and members of the group of concerned shareholders (the "Concerned Shareholders") of FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9A) (the
FSD Pharma Announces Investigational New Animal Drug Filing With the FDA to Treat Dogs With Enteropathy
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) ("FSD Pharma" or the "Company") today announced that it has submitted to the U.S. Food and Drug Administration ("FDA") an Investigational New Animal Drug Application (IND) for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat Gastrointestinal enteropathy in dogs. The application has been accepted for review.
Concerned Shareholders Issue Information Circular for FSD Pharma Inc. Shareholders' Meeting - Urge Shareholders to Vote Their Shares Using the Gold Proxy
Toronto, Ontario--(Newsfile Corp. - April 26, 2021) - On Monday, April 26, 2021, the group of concerned shareholders (the "Concerned Shareholders") of FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) (the "Company" or "FSD") filed and mailed an information circular and gold proxy to FSD's shareholders for the upcoming annual general and special meeting of FSD to be held on May 14, 2021 (the "Meeting"). The Concerned Shareholders are urging FSD shareholders to ...